Global Anti-VEGF Injection Market Growth 2024-2030
The report requires updating with new data and is sent in 48 hours after order is placed.
The global Anti-VEGF Injection market size is projected to grow from US$ million in 2023 to US$ million in 2030; it is expected to grow at a CAGR of % from 2024 to 2030.
LP Information, Inc. (LPI) ' newest research report, the “Anti-VEGF Injection Industry Forecast” looks at past sales and reviews total world Anti-VEGF Injection sales in 2023, providing a comprehensive analysis by region and market sector of projected Anti-VEGF Injection sales for 2024 through 2030. With Anti-VEGF Injection sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Anti-VEGF Injection industry.
This Insight Report provides a comprehensive analysis of the global Anti-VEGF Injection landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Anti-VEGF Injection portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Anti-VEGF Injection market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Anti-VEGF Injection and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Anti-VEGF Injection.
United States market for Anti-VEGF Injection is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.
China market for Anti-VEGF Injection is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.
Europe market for Anti-VEGF Injection is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.
Global key Anti-VEGF Injection players cover Roche, Bayer, Genentech, Novartis and Coherus BioSciences Inc., etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2023.
This report presents a comprehensive overview, market shares, and growth opportunities of Anti-VEGF Injection market by product type, application, key manufacturers and key regions and countries.
Segmentation by type
What is the 10-year outlook for the global Anti-VEGF Injection market?
What factors are driving Anti-VEGF Injection market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Anti-VEGF Injection market opportunities vary by end market size?
How does Anti-VEGF Injection break out type, application?
The global Anti-VEGF Injection market size is projected to grow from US$ million in 2023 to US$ million in 2030; it is expected to grow at a CAGR of % from 2024 to 2030.
LP Information, Inc. (LPI) ' newest research report, the “Anti-VEGF Injection Industry Forecast” looks at past sales and reviews total world Anti-VEGF Injection sales in 2023, providing a comprehensive analysis by region and market sector of projected Anti-VEGF Injection sales for 2024 through 2030. With Anti-VEGF Injection sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Anti-VEGF Injection industry.
This Insight Report provides a comprehensive analysis of the global Anti-VEGF Injection landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Anti-VEGF Injection portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Anti-VEGF Injection market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Anti-VEGF Injection and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Anti-VEGF Injection.
United States market for Anti-VEGF Injection is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.
China market for Anti-VEGF Injection is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.
Europe market for Anti-VEGF Injection is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.
Global key Anti-VEGF Injection players cover Roche, Bayer, Genentech, Novartis and Coherus BioSciences Inc., etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2023.
This report presents a comprehensive overview, market shares, and growth opportunities of Anti-VEGF Injection market by product type, application, key manufacturers and key regions and countries.
Segmentation by type
- Ranibizumab
- Bevacizumab
- Aflibercept
- Brolucizumab
- Others
- Age-related Macular Degeneration (AMD)
- Diabetic Retinopathy
- Retinal Vein Occlusion (RVO)
- Retinopathy of Prematurity (ROP)
- Uveitis
- Neovascular Glaucoma
- Others
- Americas
- United States
- Canada
- Mexico
- Brazil
- APAC
- China
- Japan
- Korea
- Southeast Asia
- India
- Australia
- Europe
- Germany
- France
- UK
- Italy
- Russia
- Middle East & Africa
- Egypt
- South Africa
- Israel
- Turkey
- GCC Countries
- Roche
- Bayer
- Genentech
- Novartis
- Coherus BioSciences Inc.
- Regeneron
- Qilu Pharmaceutical Co.,Ltd.
- Innovent Biologics
- Anke Biotechnology
- Shenzhen Kangzhe Pharmaceutical Co Ltd
- Chengdu Kanghong Pharmaceutical Group
What is the 10-year outlook for the global Anti-VEGF Injection market?
What factors are driving Anti-VEGF Injection market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Anti-VEGF Injection market opportunities vary by end market size?
How does Anti-VEGF Injection break out type, application?
1 SCOPE OF THE REPORT
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Anti-VEGF Injection Annual Sales 2019-2030
2.1.2 World Current & Future Analysis for Anti-VEGF Injection by Geographic Region, 2019, 2023 & 2030
2.1.3 World Current & Future Analysis for Anti-VEGF Injection by Country/Region, 2019, 2023 & 2030
2.2 Anti-VEGF Injection Segment by Type
2.2.1 Ranibizumab
2.2.2 Bevacizumab
2.2.3 Aflibercept
2.2.4 Brolucizumab
2.2.5 Others
2.3 Anti-VEGF Injection Sales by Type
2.3.1 Global Anti-VEGF Injection Sales Market Share by Type (2019-2024)
2.3.2 Global Anti-VEGF Injection Revenue and Market Share by Type (2019-2024)
2.3.3 Global Anti-VEGF Injection Sale Price by Type (2019-2024)
2.4 Anti-VEGF Injection Segment by Application
2.4.1 Age-related Macular Degeneration (AMD)
2.4.2 Diabetic Retinopathy
2.4.3 Retinal Vein Occlusion (RVO)
2.4.4 Retinopathy of Prematurity (ROP)
2.4.5 Uveitis
2.4.6 Neovascular Glaucoma
2.4.7 Others
2.5 Anti-VEGF Injection Sales by Application
2.5.1 Global Anti-VEGF Injection Sale Market Share by Application (2019-2024)
2.5.2 Global Anti-VEGF Injection Revenue and Market Share by Application (2019-2024)
2.5.3 Global Anti-VEGF Injection Sale Price by Application (2019-2024)
3 GLOBAL ANTI-VEGF INJECTION BY COMPANY
3.1 Global Anti-VEGF Injection Breakdown Data by Company
3.1.1 Global Anti-VEGF Injection Annual Sales by Company (2019-2024)
3.1.2 Global Anti-VEGF Injection Sales Market Share by Company (2019-2024)
3.2 Global Anti-VEGF Injection Annual Revenue by Company (2019-2024)
3.2.1 Global Anti-VEGF Injection Revenue by Company (2019-2024)
3.2.2 Global Anti-VEGF Injection Revenue Market Share by Company (2019-2024)
3.3 Global Anti-VEGF Injection Sale Price by Company
3.4 Key Manufacturers Anti-VEGF Injection Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Anti-VEGF Injection Product Location Distribution
3.4.2 Players Anti-VEGF Injection Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2019-2024)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion
4 WORLD HISTORIC REVIEW FOR ANTI-VEGF INJECTION BY GEOGRAPHIC REGION
4.1 World Historic Anti-VEGF Injection Market Size by Geographic Region (2019-2024)
4.1.1 Global Anti-VEGF Injection Annual Sales by Geographic Region (2019-2024)
4.1.2 Global Anti-VEGF Injection Annual Revenue by Geographic Region (2019-2024)
4.2 World Historic Anti-VEGF Injection Market Size by Country/Region (2019-2024)
4.2.1 Global Anti-VEGF Injection Annual Sales by Country/Region (2019-2024)
4.2.2 Global Anti-VEGF Injection Annual Revenue by Country/Region (2019-2024)
4.3 Americas Anti-VEGF Injection Sales Growth
4.4 APAC Anti-VEGF Injection Sales Growth
4.5 Europe Anti-VEGF Injection Sales Growth
4.6 Middle East & Africa Anti-VEGF Injection Sales Growth
5 AMERICAS
5.1 Americas Anti-VEGF Injection Sales by Country
5.1.1 Americas Anti-VEGF Injection Sales by Country (2019-2024)
5.1.2 Americas Anti-VEGF Injection Revenue by Country (2019-2024)
5.2 Americas Anti-VEGF Injection Sales by Type
5.3 Americas Anti-VEGF Injection Sales by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Anti-VEGF Injection Sales by Region
6.1.1 APAC Anti-VEGF Injection Sales by Region (2019-2024)
6.1.2 APAC Anti-VEGF Injection Revenue by Region (2019-2024)
6.2 APAC Anti-VEGF Injection Sales by Type
6.3 APAC Anti-VEGF Injection Sales by Application
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe Anti-VEGF Injection by Country
7.1.1 Europe Anti-VEGF Injection Sales by Country (2019-2024)
7.1.2 Europe Anti-VEGF Injection Revenue by Country (2019-2024)
7.2 Europe Anti-VEGF Injection Sales by Type
7.3 Europe Anti-VEGF Injection Sales by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Anti-VEGF Injection by Country
8.1.1 Middle East & Africa Anti-VEGF Injection Sales by Country (2019-2024)
8.1.2 Middle East & Africa Anti-VEGF Injection Revenue by Country (2019-2024)
8.2 Middle East & Africa Anti-VEGF Injection Sales by Type
8.3 Middle East & Africa Anti-VEGF Injection Sales by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Anti-VEGF Injection
10.3 Manufacturing Process Analysis of Anti-VEGF Injection
10.4 Industry Chain Structure of Anti-VEGF Injection
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Anti-VEGF Injection Distributors
11.3 Anti-VEGF Injection Customer
12 WORLD FORECAST REVIEW FOR ANTI-VEGF INJECTION BY GEOGRAPHIC REGION
12.1 Global Anti-VEGF Injection Market Size Forecast by Region
12.1.1 Global Anti-VEGF Injection Forecast by Region (2025-2030)
12.1.2 Global Anti-VEGF Injection Annual Revenue Forecast by Region (2025-2030)
12.2 Americas Forecast by Country
12.3 APAC Forecast by Region
12.4 Europe Forecast by Country
12.5 Middle East & Africa Forecast by Country
12.6 Global Anti-VEGF Injection Forecast by Type
12.7 Global Anti-VEGF Injection Forecast by Application
13 KEY PLAYERS ANALYSIS
13.1 Roche
13.1.1 Roche Company Information
13.1.2 Roche Anti-VEGF Injection Product Portfolios and Specifications
13.1.3 Roche Anti-VEGF Injection Sales, Revenue, Price and Gross Margin (2019-2024)
13.1.4 Roche Main Business Overview
13.1.5 Roche Latest Developments
13.2 Bayer
13.2.1 Bayer Company Information
13.2.2 Bayer Anti-VEGF Injection Product Portfolios and Specifications
13.2.3 Bayer Anti-VEGF Injection Sales, Revenue, Price and Gross Margin (2019-2024)
13.2.4 Bayer Main Business Overview
13.2.5 Bayer Latest Developments
13.3 Genentech
13.3.1 Genentech Company Information
13.3.2 Genentech Anti-VEGF Injection Product Portfolios and Specifications
13.3.3 Genentech Anti-VEGF Injection Sales, Revenue, Price and Gross Margin (2019-2024)
13.3.4 Genentech Main Business Overview
13.3.5 Genentech Latest Developments
13.4 Novartis
13.4.1 Novartis Company Information
13.4.2 Novartis Anti-VEGF Injection Product Portfolios and Specifications
13.4.3 Novartis Anti-VEGF Injection Sales, Revenue, Price and Gross Margin (2019-2024)
13.4.4 Novartis Main Business Overview
13.4.5 Novartis Latest Developments
13.5 Coherus BioSciences Inc.
13.5.1 Coherus BioSciences Inc. Company Information
13.5.2 Coherus BioSciences Inc. Anti-VEGF Injection Product Portfolios and Specifications
13.5.3 Coherus BioSciences Inc. Anti-VEGF Injection Sales, Revenue, Price and Gross Margin (2019-2024)
13.5.4 Coherus BioSciences Inc. Main Business Overview
13.5.5 Coherus BioSciences Inc. Latest Developments
13.6 Regeneron
13.6.1 Regeneron Company Information
13.6.2 Regeneron Anti-VEGF Injection Product Portfolios and Specifications
13.6.3 Regeneron Anti-VEGF Injection Sales, Revenue, Price and Gross Margin (2019-2024)
13.6.4 Regeneron Main Business Overview
13.6.5 Regeneron Latest Developments
13.7 Qilu Pharmaceutical Co.,Ltd.
13.7.1 Qilu Pharmaceutical Co.,Ltd. Company Information
13.7.2 Qilu Pharmaceutical Co.,Ltd. Anti-VEGF Injection Product Portfolios and Specifications
13.7.3 Qilu Pharmaceutical Co.,Ltd. Anti-VEGF Injection Sales, Revenue, Price and Gross Margin (2019-2024)
13.7.4 Qilu Pharmaceutical Co.,Ltd. Main Business Overview
13.7.5 Qilu Pharmaceutical Co.,Ltd. Latest Developments
13.8 Innovent Biologics
13.8.1 Innovent Biologics Company Information
13.8.2 Innovent Biologics Anti-VEGF Injection Product Portfolios and Specifications
13.8.3 Innovent Biologics Anti-VEGF Injection Sales, Revenue, Price and Gross Margin (2019-2024)
13.8.4 Innovent Biologics Main Business Overview
13.8.5 Innovent Biologics Latest Developments
13.9 Anke Biotechnology
13.9.1 Anke Biotechnology Company Information
13.9.2 Anke Biotechnology Anti-VEGF Injection Product Portfolios and Specifications
13.9.3 Anke Biotechnology Anti-VEGF Injection Sales, Revenue, Price and Gross Margin (2019-2024)
13.9.4 Anke Biotechnology Main Business Overview
13.9.5 Anke Biotechnology Latest Developments
13.10 Shenzhen Kangzhe Pharmaceutical Co Ltd
13.10.1 Shenzhen Kangzhe Pharmaceutical Co Ltd Company Information
13.10.2 Shenzhen Kangzhe Pharmaceutical Co Ltd Anti-VEGF Injection Product Portfolios and Specifications
13.10.3 Shenzhen Kangzhe Pharmaceutical Co Ltd Anti-VEGF Injection Sales, Revenue, Price and Gross Margin (2019-2024)
13.10.4 Shenzhen Kangzhe Pharmaceutical Co Ltd Main Business Overview
13.10.5 Shenzhen Kangzhe Pharmaceutical Co Ltd Latest Developments
13.11 Chengdu Kanghong Pharmaceutical Group
13.11.1 Chengdu Kanghong Pharmaceutical Group Company Information
13.11.2 Chengdu Kanghong Pharmaceutical Group Anti-VEGF Injection Product Portfolios and Specifications
13.11.3 Chengdu Kanghong Pharmaceutical Group Anti-VEGF Injection Sales, Revenue, Price and Gross Margin (2019-2024)
13.11.4 Chengdu Kanghong Pharmaceutical Group Main Business Overview
13.11.5 Chengdu Kanghong Pharmaceutical Group Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Anti-VEGF Injection Annual Sales 2019-2030
2.1.2 World Current & Future Analysis for Anti-VEGF Injection by Geographic Region, 2019, 2023 & 2030
2.1.3 World Current & Future Analysis for Anti-VEGF Injection by Country/Region, 2019, 2023 & 2030
2.2 Anti-VEGF Injection Segment by Type
2.2.1 Ranibizumab
2.2.2 Bevacizumab
2.2.3 Aflibercept
2.2.4 Brolucizumab
2.2.5 Others
2.3 Anti-VEGF Injection Sales by Type
2.3.1 Global Anti-VEGF Injection Sales Market Share by Type (2019-2024)
2.3.2 Global Anti-VEGF Injection Revenue and Market Share by Type (2019-2024)
2.3.3 Global Anti-VEGF Injection Sale Price by Type (2019-2024)
2.4 Anti-VEGF Injection Segment by Application
2.4.1 Age-related Macular Degeneration (AMD)
2.4.2 Diabetic Retinopathy
2.4.3 Retinal Vein Occlusion (RVO)
2.4.4 Retinopathy of Prematurity (ROP)
2.4.5 Uveitis
2.4.6 Neovascular Glaucoma
2.4.7 Others
2.5 Anti-VEGF Injection Sales by Application
2.5.1 Global Anti-VEGF Injection Sale Market Share by Application (2019-2024)
2.5.2 Global Anti-VEGF Injection Revenue and Market Share by Application (2019-2024)
2.5.3 Global Anti-VEGF Injection Sale Price by Application (2019-2024)
3 GLOBAL ANTI-VEGF INJECTION BY COMPANY
3.1 Global Anti-VEGF Injection Breakdown Data by Company
3.1.1 Global Anti-VEGF Injection Annual Sales by Company (2019-2024)
3.1.2 Global Anti-VEGF Injection Sales Market Share by Company (2019-2024)
3.2 Global Anti-VEGF Injection Annual Revenue by Company (2019-2024)
3.2.1 Global Anti-VEGF Injection Revenue by Company (2019-2024)
3.2.2 Global Anti-VEGF Injection Revenue Market Share by Company (2019-2024)
3.3 Global Anti-VEGF Injection Sale Price by Company
3.4 Key Manufacturers Anti-VEGF Injection Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Anti-VEGF Injection Product Location Distribution
3.4.2 Players Anti-VEGF Injection Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2019-2024)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion
4 WORLD HISTORIC REVIEW FOR ANTI-VEGF INJECTION BY GEOGRAPHIC REGION
4.1 World Historic Anti-VEGF Injection Market Size by Geographic Region (2019-2024)
4.1.1 Global Anti-VEGF Injection Annual Sales by Geographic Region (2019-2024)
4.1.2 Global Anti-VEGF Injection Annual Revenue by Geographic Region (2019-2024)
4.2 World Historic Anti-VEGF Injection Market Size by Country/Region (2019-2024)
4.2.1 Global Anti-VEGF Injection Annual Sales by Country/Region (2019-2024)
4.2.2 Global Anti-VEGF Injection Annual Revenue by Country/Region (2019-2024)
4.3 Americas Anti-VEGF Injection Sales Growth
4.4 APAC Anti-VEGF Injection Sales Growth
4.5 Europe Anti-VEGF Injection Sales Growth
4.6 Middle East & Africa Anti-VEGF Injection Sales Growth
5 AMERICAS
5.1 Americas Anti-VEGF Injection Sales by Country
5.1.1 Americas Anti-VEGF Injection Sales by Country (2019-2024)
5.1.2 Americas Anti-VEGF Injection Revenue by Country (2019-2024)
5.2 Americas Anti-VEGF Injection Sales by Type
5.3 Americas Anti-VEGF Injection Sales by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Anti-VEGF Injection Sales by Region
6.1.1 APAC Anti-VEGF Injection Sales by Region (2019-2024)
6.1.2 APAC Anti-VEGF Injection Revenue by Region (2019-2024)
6.2 APAC Anti-VEGF Injection Sales by Type
6.3 APAC Anti-VEGF Injection Sales by Application
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe Anti-VEGF Injection by Country
7.1.1 Europe Anti-VEGF Injection Sales by Country (2019-2024)
7.1.2 Europe Anti-VEGF Injection Revenue by Country (2019-2024)
7.2 Europe Anti-VEGF Injection Sales by Type
7.3 Europe Anti-VEGF Injection Sales by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Anti-VEGF Injection by Country
8.1.1 Middle East & Africa Anti-VEGF Injection Sales by Country (2019-2024)
8.1.2 Middle East & Africa Anti-VEGF Injection Revenue by Country (2019-2024)
8.2 Middle East & Africa Anti-VEGF Injection Sales by Type
8.3 Middle East & Africa Anti-VEGF Injection Sales by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Anti-VEGF Injection
10.3 Manufacturing Process Analysis of Anti-VEGF Injection
10.4 Industry Chain Structure of Anti-VEGF Injection
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Anti-VEGF Injection Distributors
11.3 Anti-VEGF Injection Customer
12 WORLD FORECAST REVIEW FOR ANTI-VEGF INJECTION BY GEOGRAPHIC REGION
12.1 Global Anti-VEGF Injection Market Size Forecast by Region
12.1.1 Global Anti-VEGF Injection Forecast by Region (2025-2030)
12.1.2 Global Anti-VEGF Injection Annual Revenue Forecast by Region (2025-2030)
12.2 Americas Forecast by Country
12.3 APAC Forecast by Region
12.4 Europe Forecast by Country
12.5 Middle East & Africa Forecast by Country
12.6 Global Anti-VEGF Injection Forecast by Type
12.7 Global Anti-VEGF Injection Forecast by Application
13 KEY PLAYERS ANALYSIS
13.1 Roche
13.1.1 Roche Company Information
13.1.2 Roche Anti-VEGF Injection Product Portfolios and Specifications
13.1.3 Roche Anti-VEGF Injection Sales, Revenue, Price and Gross Margin (2019-2024)
13.1.4 Roche Main Business Overview
13.1.5 Roche Latest Developments
13.2 Bayer
13.2.1 Bayer Company Information
13.2.2 Bayer Anti-VEGF Injection Product Portfolios and Specifications
13.2.3 Bayer Anti-VEGF Injection Sales, Revenue, Price and Gross Margin (2019-2024)
13.2.4 Bayer Main Business Overview
13.2.5 Bayer Latest Developments
13.3 Genentech
13.3.1 Genentech Company Information
13.3.2 Genentech Anti-VEGF Injection Product Portfolios and Specifications
13.3.3 Genentech Anti-VEGF Injection Sales, Revenue, Price and Gross Margin (2019-2024)
13.3.4 Genentech Main Business Overview
13.3.5 Genentech Latest Developments
13.4 Novartis
13.4.1 Novartis Company Information
13.4.2 Novartis Anti-VEGF Injection Product Portfolios and Specifications
13.4.3 Novartis Anti-VEGF Injection Sales, Revenue, Price and Gross Margin (2019-2024)
13.4.4 Novartis Main Business Overview
13.4.5 Novartis Latest Developments
13.5 Coherus BioSciences Inc.
13.5.1 Coherus BioSciences Inc. Company Information
13.5.2 Coherus BioSciences Inc. Anti-VEGF Injection Product Portfolios and Specifications
13.5.3 Coherus BioSciences Inc. Anti-VEGF Injection Sales, Revenue, Price and Gross Margin (2019-2024)
13.5.4 Coherus BioSciences Inc. Main Business Overview
13.5.5 Coherus BioSciences Inc. Latest Developments
13.6 Regeneron
13.6.1 Regeneron Company Information
13.6.2 Regeneron Anti-VEGF Injection Product Portfolios and Specifications
13.6.3 Regeneron Anti-VEGF Injection Sales, Revenue, Price and Gross Margin (2019-2024)
13.6.4 Regeneron Main Business Overview
13.6.5 Regeneron Latest Developments
13.7 Qilu Pharmaceutical Co.,Ltd.
13.7.1 Qilu Pharmaceutical Co.,Ltd. Company Information
13.7.2 Qilu Pharmaceutical Co.,Ltd. Anti-VEGF Injection Product Portfolios and Specifications
13.7.3 Qilu Pharmaceutical Co.,Ltd. Anti-VEGF Injection Sales, Revenue, Price and Gross Margin (2019-2024)
13.7.4 Qilu Pharmaceutical Co.,Ltd. Main Business Overview
13.7.5 Qilu Pharmaceutical Co.,Ltd. Latest Developments
13.8 Innovent Biologics
13.8.1 Innovent Biologics Company Information
13.8.2 Innovent Biologics Anti-VEGF Injection Product Portfolios and Specifications
13.8.3 Innovent Biologics Anti-VEGF Injection Sales, Revenue, Price and Gross Margin (2019-2024)
13.8.4 Innovent Biologics Main Business Overview
13.8.5 Innovent Biologics Latest Developments
13.9 Anke Biotechnology
13.9.1 Anke Biotechnology Company Information
13.9.2 Anke Biotechnology Anti-VEGF Injection Product Portfolios and Specifications
13.9.3 Anke Biotechnology Anti-VEGF Injection Sales, Revenue, Price and Gross Margin (2019-2024)
13.9.4 Anke Biotechnology Main Business Overview
13.9.5 Anke Biotechnology Latest Developments
13.10 Shenzhen Kangzhe Pharmaceutical Co Ltd
13.10.1 Shenzhen Kangzhe Pharmaceutical Co Ltd Company Information
13.10.2 Shenzhen Kangzhe Pharmaceutical Co Ltd Anti-VEGF Injection Product Portfolios and Specifications
13.10.3 Shenzhen Kangzhe Pharmaceutical Co Ltd Anti-VEGF Injection Sales, Revenue, Price and Gross Margin (2019-2024)
13.10.4 Shenzhen Kangzhe Pharmaceutical Co Ltd Main Business Overview
13.10.5 Shenzhen Kangzhe Pharmaceutical Co Ltd Latest Developments
13.11 Chengdu Kanghong Pharmaceutical Group
13.11.1 Chengdu Kanghong Pharmaceutical Group Company Information
13.11.2 Chengdu Kanghong Pharmaceutical Group Anti-VEGF Injection Product Portfolios and Specifications
13.11.3 Chengdu Kanghong Pharmaceutical Group Anti-VEGF Injection Sales, Revenue, Price and Gross Margin (2019-2024)
13.11.4 Chengdu Kanghong Pharmaceutical Group Main Business Overview
13.11.5 Chengdu Kanghong Pharmaceutical Group Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
LIST OF TABLES
Table 1. Anti-VEGF Injection Annual Sales CAGR by Geographic Region (2019, 2023 & 2030) & ($ millions)
Table 2. Anti-VEGF Injection Annual Sales CAGR by Country/Region (2019, 2023 & 2030) & ($ millions)
Table 3. Major Players of Ranibizumab
Table 4. Major Players of Bevacizumab
Table 5. Major Players of Aflibercept
Table 6. Major Players of Brolucizumab
Table 7. Major Players of Others
Table 8. Global Anti-VEGF Injection Sales by Type (2019-2024) & (K Units)
Table 9. Global Anti-VEGF Injection Sales Market Share by Type (2019-2024)
Table 10. Global Anti-VEGF Injection Revenue by Type (2019-2024) & ($ million)
Table 11. Global Anti-VEGF Injection Revenue Market Share by Type (2019-2024)
Table 12. Global Anti-VEGF Injection Sale Price by Type (2019-2024) & (US$/Unit)
Table 13. Global Anti-VEGF Injection Sales by Application (2019-2024) & (K Units)
Table 14. Global Anti-VEGF Injection Sales Market Share by Application (2019-2024)
Table 15. Global Anti-VEGF Injection Revenue by Application (2019-2024)
Table 16. Global Anti-VEGF Injection Revenue Market Share by Application (2019-2024)
Table 17. Global Anti-VEGF Injection Sale Price by Application (2019-2024) & (US$/Unit)
Table 18. Global Anti-VEGF Injection Sales by Company (2019-2024) & (K Units)
Table 19. Global Anti-VEGF Injection Sales Market Share by Company (2019-2024)
Table 20. Global Anti-VEGF Injection Revenue by Company (2019-2024) ($ Millions)
Table 21. Global Anti-VEGF Injection Revenue Market Share by Company (2019-2024)
Table 22. Global Anti-VEGF Injection Sale Price by Company (2019-2024) & (US$/Unit)
Table 23. Key Manufacturers Anti-VEGF Injection Producing Area Distribution and Sales Area
Table 24. Players Anti-VEGF Injection Products Offered
Table 25. Anti-VEGF Injection Concentration Ratio (CR3, CR5 and CR10) & (2019-2024)
Table 26. New Products and Potential Entrants
Table 27. Mergers & Acquisitions, Expansion
Table 28. Global Anti-VEGF Injection Sales by Geographic Region (2019-2024) & (K Units)
Table 29. Global Anti-VEGF Injection Sales Market Share Geographic Region (2019-2024)
Table 30. Global Anti-VEGF Injection Revenue by Geographic Region (2019-2024) & ($ millions)
Table 31. Global Anti-VEGF Injection Revenue Market Share by Geographic Region (2019-2024)
Table 32. Global Anti-VEGF Injection Sales by Country/Region (2019-2024) & (K Units)
Table 33. Global Anti-VEGF Injection Sales Market Share by Country/Region (2019-2024)
Table 34. Global Anti-VEGF Injection Revenue by Country/Region (2019-2024) & ($ millions)
Table 35. Global Anti-VEGF Injection Revenue Market Share by Country/Region (2019-2024)
Table 36. Americas Anti-VEGF Injection Sales by Country (2019-2024) & (K Units)
Table 37. Americas Anti-VEGF Injection Sales Market Share by Country (2019-2024)
Table 38. Americas Anti-VEGF Injection Revenue by Country (2019-2024) & ($ Millions)
Table 39. Americas Anti-VEGF Injection Revenue Market Share by Country (2019-2024)
Table 40. Americas Anti-VEGF Injection Sales by Type (2019-2024) & (K Units)
Table 41. Americas Anti-VEGF Injection Sales by Application (2019-2024) & (K Units)
Table 42. APAC Anti-VEGF Injection Sales by Region (2019-2024) & (K Units)
Table 43. APAC Anti-VEGF Injection Sales Market Share by Region (2019-2024)
Table 44. APAC Anti-VEGF Injection Revenue by Region (2019-2024) & ($ Millions)
Table 45. APAC Anti-VEGF Injection Revenue Market Share by Region (2019-2024)
Table 46. APAC Anti-VEGF Injection Sales by Type (2019-2024) & (K Units)
Table 47. APAC Anti-VEGF Injection Sales by Application (2019-2024) & (K Units)
Table 48. Europe Anti-VEGF Injection Sales by Country (2019-2024) & (K Units)
Table 49. Europe Anti-VEGF Injection Sales Market Share by Country (2019-2024)
Table 50. Europe Anti-VEGF Injection Revenue by Country (2019-2024) & ($ Millions)
Table 51. Europe Anti-VEGF Injection Revenue Market Share by Country (2019-2024)
Table 52. Europe Anti-VEGF Injection Sales by Type (2019-2024) & (K Units)
Table 53. Europe Anti-VEGF Injection Sales by Application (2019-2024) & (K Units)
Table 54. Middle East & Africa Anti-VEGF Injection Sales by Country (2019-2024) & (K Units)
Table 55. Middle East & Africa Anti-VEGF Injection Sales Market Share by Country (2019-2024)
Table 56. Middle East & Africa Anti-VEGF Injection Revenue by Country (2019-2024) & ($ Millions)
Table 57. Middle East & Africa Anti-VEGF Injection Revenue Market Share by Country (2019-2024)
Table 58. Middle East & Africa Anti-VEGF Injection Sales by Type (2019-2024) & (K Units)
Table 59. Middle East & Africa Anti-VEGF Injection Sales by Application (2019-2024) & (K Units)
Table 60. Key Market Drivers & Growth Opportunities of Anti-VEGF Injection
Table 61. Key Market Challenges & Risks of Anti-VEGF Injection
Table 62. Key Industry Trends of Anti-VEGF Injection
Table 63. Anti-VEGF Injection Raw Material
Table 64. Key Suppliers of Raw Materials
Table 65. Anti-VEGF Injection Distributors List
Table 66. Anti-VEGF Injection Customer List
Table 67. Global Anti-VEGF Injection Sales Forecast by Region (2025-2030) & (K Units)
Table 68. Global Anti-VEGF Injection Revenue Forecast by Region (2025-2030) & ($ millions)
Table 69. Americas Anti-VEGF Injection Sales Forecast by Country (2025-2030) & (K Units)
Table 70. Americas Anti-VEGF Injection Revenue Forecast by Country (2025-2030) & ($ millions)
Table 71. APAC Anti-VEGF Injection Sales Forecast by Region (2025-2030) & (K Units)
Table 72. APAC Anti-VEGF Injection Revenue Forecast by Region (2025-2030) & ($ millions)
Table 73. Europe Anti-VEGF Injection Sales Forecast by Country (2025-2030) & (K Units)
Table 74. Europe Anti-VEGF Injection Revenue Forecast by Country (2025-2030) & ($ millions)
Table 75. Middle East & Africa Anti-VEGF Injection Sales Forecast by Country (2025-2030) & (K Units)
Table 76. Middle East & Africa Anti-VEGF Injection Revenue Forecast by Country (2025-2030) & ($ millions)
Table 77. Global Anti-VEGF Injection Sales Forecast by Type (2025-2030) & (K Units)
Table 78. Global Anti-VEGF Injection Revenue Forecast by Type (2025-2030) & ($ Millions)
Table 79. Global Anti-VEGF Injection Sales Forecast by Application (2025-2030) & (K Units)
Table 80. Global Anti-VEGF Injection Revenue Forecast by Application (2025-2030) & ($ Millions)
Table 81. Roche Basic Information, Anti-VEGF Injection Manufacturing Base, Sales Area and Its Competitors
Table 82. Roche Anti-VEGF Injection Product Portfolios and Specifications
Table 83. Roche Anti-VEGF Injection Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 84. Roche Main Business
Table 85. Roche Latest Developments
Table 86. Bayer Basic Information, Anti-VEGF Injection Manufacturing Base, Sales Area and Its Competitors
Table 87. Bayer Anti-VEGF Injection Product Portfolios and Specifications
Table 88. Bayer Anti-VEGF Injection Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 89. Bayer Main Business
Table 90. Bayer Latest Developments
Table 91. Genentech Basic Information, Anti-VEGF Injection Manufacturing Base, Sales Area and Its Competitors
Table 92. Genentech Anti-VEGF Injection Product Portfolios and Specifications
Table 93. Genentech Anti-VEGF Injection Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 94. Genentech Main Business
Table 95. Genentech Latest Developments
Table 96. Novartis Basic Information, Anti-VEGF Injection Manufacturing Base, Sales Area and Its Competitors
Table 97. Novartis Anti-VEGF Injection Product Portfolios and Specifications
Table 98. Novartis Anti-VEGF Injection Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 99. Novartis Main Business
Table 100. Novartis Latest Developments
Table 101. Coherus BioSciences Inc. Basic Information, Anti-VEGF Injection Manufacturing Base, Sales Area and Its Competitors
Table 102. Coherus BioSciences Inc. Anti-VEGF Injection Product Portfolios and Specifications
Table 103. Coherus BioSciences Inc. Anti-VEGF Injection Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 104. Coherus BioSciences Inc. Main Business
Table 105. Coherus BioSciences Inc. Latest Developments
Table 106. Regeneron Basic Information, Anti-VEGF Injection Manufacturing Base, Sales Area and Its Competitors
Table 107. Regeneron Anti-VEGF Injection Product Portfolios and Specifications
Table 108. Regeneron Anti-VEGF Injection Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 109. Regeneron Main Business
Table 110. Regeneron Latest Developments
Table 111. Qilu Pharmaceutical Co.,Ltd. Basic Information, Anti-VEGF Injection Manufacturing Base, Sales Area and Its Competitors
Table 112. Qilu Pharmaceutical Co.,Ltd. Anti-VEGF Injection Product Portfolios and Specifications
Table 113. Qilu Pharmaceutical Co.,Ltd. Anti-VEGF Injection Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 114. Qilu Pharmaceutical Co.,Ltd. Main Business
Table 115. Qilu Pharmaceutical Co.,Ltd. Latest Developments
Table 116. Innovent Biologics Basic Information, Anti-VEGF Injection Manufacturing Base, Sales Area and Its Competitors
Table 117. Innovent Biologics Anti-VEGF Injection Product Portfolios and Specifications
Table 118. Innovent Biologics Anti-VEGF Injection Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 119. Innovent Biologics Main Business
Table 120. Innovent Biologics Latest Developments
Table 121. Anke Biotechnology Basic Information, Anti-VEGF Injection Manufacturing Base, Sales Area and Its Competitors
Table 122. Anke Biotechnology Anti-VEGF Injection Product Portfolios and Specifications
Table 123. Anke Biotechnology Anti-VEGF Injection Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 124. Anke Biotechnology Main Business
Table 125. Anke Biotechnology Latest Developments
Table 126. Shenzhen Kangzhe Pharmaceutical Co Ltd Basic Information, Anti-VEGF Injection Manufacturing Base, Sales Area and Its Competitors
Table 127. Shenzhen Kangzhe Pharmaceutical Co Ltd Anti-VEGF Injection Product Portfolios and Specifications
Table 128. Shenzhen Kangzhe Pharmaceutical Co Ltd Anti-VEGF Injection Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 129. Shenzhen Kangzhe Pharmaceutical Co Ltd Main Business
Table 130. Shenzhen Kangzhe Pharmaceutical Co Ltd Latest Developments
Table 131. Chengdu Kanghong Pharmaceutical Group Basic Information, Anti-VEGF Injection Manufacturing Base, Sales Area and Its Competitors
Table 132. Chengdu Kanghong Pharmaceutical Group Anti-VEGF Injection Product Portfolios and Specifications
Table 133. Chengdu Kanghong Pharmaceutical Group Anti-VEGF Injection Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 134. Chengdu Kanghong Pharmaceutical Group Main Business
Table 135. Chengdu Kanghong Pharmaceutical Group Latest Developments
Table 1. Anti-VEGF Injection Annual Sales CAGR by Geographic Region (2019, 2023 & 2030) & ($ millions)
Table 2. Anti-VEGF Injection Annual Sales CAGR by Country/Region (2019, 2023 & 2030) & ($ millions)
Table 3. Major Players of Ranibizumab
Table 4. Major Players of Bevacizumab
Table 5. Major Players of Aflibercept
Table 6. Major Players of Brolucizumab
Table 7. Major Players of Others
Table 8. Global Anti-VEGF Injection Sales by Type (2019-2024) & (K Units)
Table 9. Global Anti-VEGF Injection Sales Market Share by Type (2019-2024)
Table 10. Global Anti-VEGF Injection Revenue by Type (2019-2024) & ($ million)
Table 11. Global Anti-VEGF Injection Revenue Market Share by Type (2019-2024)
Table 12. Global Anti-VEGF Injection Sale Price by Type (2019-2024) & (US$/Unit)
Table 13. Global Anti-VEGF Injection Sales by Application (2019-2024) & (K Units)
Table 14. Global Anti-VEGF Injection Sales Market Share by Application (2019-2024)
Table 15. Global Anti-VEGF Injection Revenue by Application (2019-2024)
Table 16. Global Anti-VEGF Injection Revenue Market Share by Application (2019-2024)
Table 17. Global Anti-VEGF Injection Sale Price by Application (2019-2024) & (US$/Unit)
Table 18. Global Anti-VEGF Injection Sales by Company (2019-2024) & (K Units)
Table 19. Global Anti-VEGF Injection Sales Market Share by Company (2019-2024)
Table 20. Global Anti-VEGF Injection Revenue by Company (2019-2024) ($ Millions)
Table 21. Global Anti-VEGF Injection Revenue Market Share by Company (2019-2024)
Table 22. Global Anti-VEGF Injection Sale Price by Company (2019-2024) & (US$/Unit)
Table 23. Key Manufacturers Anti-VEGF Injection Producing Area Distribution and Sales Area
Table 24. Players Anti-VEGF Injection Products Offered
Table 25. Anti-VEGF Injection Concentration Ratio (CR3, CR5 and CR10) & (2019-2024)
Table 26. New Products and Potential Entrants
Table 27. Mergers & Acquisitions, Expansion
Table 28. Global Anti-VEGF Injection Sales by Geographic Region (2019-2024) & (K Units)
Table 29. Global Anti-VEGF Injection Sales Market Share Geographic Region (2019-2024)
Table 30. Global Anti-VEGF Injection Revenue by Geographic Region (2019-2024) & ($ millions)
Table 31. Global Anti-VEGF Injection Revenue Market Share by Geographic Region (2019-2024)
Table 32. Global Anti-VEGF Injection Sales by Country/Region (2019-2024) & (K Units)
Table 33. Global Anti-VEGF Injection Sales Market Share by Country/Region (2019-2024)
Table 34. Global Anti-VEGF Injection Revenue by Country/Region (2019-2024) & ($ millions)
Table 35. Global Anti-VEGF Injection Revenue Market Share by Country/Region (2019-2024)
Table 36. Americas Anti-VEGF Injection Sales by Country (2019-2024) & (K Units)
Table 37. Americas Anti-VEGF Injection Sales Market Share by Country (2019-2024)
Table 38. Americas Anti-VEGF Injection Revenue by Country (2019-2024) & ($ Millions)
Table 39. Americas Anti-VEGF Injection Revenue Market Share by Country (2019-2024)
Table 40. Americas Anti-VEGF Injection Sales by Type (2019-2024) & (K Units)
Table 41. Americas Anti-VEGF Injection Sales by Application (2019-2024) & (K Units)
Table 42. APAC Anti-VEGF Injection Sales by Region (2019-2024) & (K Units)
Table 43. APAC Anti-VEGF Injection Sales Market Share by Region (2019-2024)
Table 44. APAC Anti-VEGF Injection Revenue by Region (2019-2024) & ($ Millions)
Table 45. APAC Anti-VEGF Injection Revenue Market Share by Region (2019-2024)
Table 46. APAC Anti-VEGF Injection Sales by Type (2019-2024) & (K Units)
Table 47. APAC Anti-VEGF Injection Sales by Application (2019-2024) & (K Units)
Table 48. Europe Anti-VEGF Injection Sales by Country (2019-2024) & (K Units)
Table 49. Europe Anti-VEGF Injection Sales Market Share by Country (2019-2024)
Table 50. Europe Anti-VEGF Injection Revenue by Country (2019-2024) & ($ Millions)
Table 51. Europe Anti-VEGF Injection Revenue Market Share by Country (2019-2024)
Table 52. Europe Anti-VEGF Injection Sales by Type (2019-2024) & (K Units)
Table 53. Europe Anti-VEGF Injection Sales by Application (2019-2024) & (K Units)
Table 54. Middle East & Africa Anti-VEGF Injection Sales by Country (2019-2024) & (K Units)
Table 55. Middle East & Africa Anti-VEGF Injection Sales Market Share by Country (2019-2024)
Table 56. Middle East & Africa Anti-VEGF Injection Revenue by Country (2019-2024) & ($ Millions)
Table 57. Middle East & Africa Anti-VEGF Injection Revenue Market Share by Country (2019-2024)
Table 58. Middle East & Africa Anti-VEGF Injection Sales by Type (2019-2024) & (K Units)
Table 59. Middle East & Africa Anti-VEGF Injection Sales by Application (2019-2024) & (K Units)
Table 60. Key Market Drivers & Growth Opportunities of Anti-VEGF Injection
Table 61. Key Market Challenges & Risks of Anti-VEGF Injection
Table 62. Key Industry Trends of Anti-VEGF Injection
Table 63. Anti-VEGF Injection Raw Material
Table 64. Key Suppliers of Raw Materials
Table 65. Anti-VEGF Injection Distributors List
Table 66. Anti-VEGF Injection Customer List
Table 67. Global Anti-VEGF Injection Sales Forecast by Region (2025-2030) & (K Units)
Table 68. Global Anti-VEGF Injection Revenue Forecast by Region (2025-2030) & ($ millions)
Table 69. Americas Anti-VEGF Injection Sales Forecast by Country (2025-2030) & (K Units)
Table 70. Americas Anti-VEGF Injection Revenue Forecast by Country (2025-2030) & ($ millions)
Table 71. APAC Anti-VEGF Injection Sales Forecast by Region (2025-2030) & (K Units)
Table 72. APAC Anti-VEGF Injection Revenue Forecast by Region (2025-2030) & ($ millions)
Table 73. Europe Anti-VEGF Injection Sales Forecast by Country (2025-2030) & (K Units)
Table 74. Europe Anti-VEGF Injection Revenue Forecast by Country (2025-2030) & ($ millions)
Table 75. Middle East & Africa Anti-VEGF Injection Sales Forecast by Country (2025-2030) & (K Units)
Table 76. Middle East & Africa Anti-VEGF Injection Revenue Forecast by Country (2025-2030) & ($ millions)
Table 77. Global Anti-VEGF Injection Sales Forecast by Type (2025-2030) & (K Units)
Table 78. Global Anti-VEGF Injection Revenue Forecast by Type (2025-2030) & ($ Millions)
Table 79. Global Anti-VEGF Injection Sales Forecast by Application (2025-2030) & (K Units)
Table 80. Global Anti-VEGF Injection Revenue Forecast by Application (2025-2030) & ($ Millions)
Table 81. Roche Basic Information, Anti-VEGF Injection Manufacturing Base, Sales Area and Its Competitors
Table 82. Roche Anti-VEGF Injection Product Portfolios and Specifications
Table 83. Roche Anti-VEGF Injection Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 84. Roche Main Business
Table 85. Roche Latest Developments
Table 86. Bayer Basic Information, Anti-VEGF Injection Manufacturing Base, Sales Area and Its Competitors
Table 87. Bayer Anti-VEGF Injection Product Portfolios and Specifications
Table 88. Bayer Anti-VEGF Injection Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 89. Bayer Main Business
Table 90. Bayer Latest Developments
Table 91. Genentech Basic Information, Anti-VEGF Injection Manufacturing Base, Sales Area and Its Competitors
Table 92. Genentech Anti-VEGF Injection Product Portfolios and Specifications
Table 93. Genentech Anti-VEGF Injection Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 94. Genentech Main Business
Table 95. Genentech Latest Developments
Table 96. Novartis Basic Information, Anti-VEGF Injection Manufacturing Base, Sales Area and Its Competitors
Table 97. Novartis Anti-VEGF Injection Product Portfolios and Specifications
Table 98. Novartis Anti-VEGF Injection Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 99. Novartis Main Business
Table 100. Novartis Latest Developments
Table 101. Coherus BioSciences Inc. Basic Information, Anti-VEGF Injection Manufacturing Base, Sales Area and Its Competitors
Table 102. Coherus BioSciences Inc. Anti-VEGF Injection Product Portfolios and Specifications
Table 103. Coherus BioSciences Inc. Anti-VEGF Injection Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 104. Coherus BioSciences Inc. Main Business
Table 105. Coherus BioSciences Inc. Latest Developments
Table 106. Regeneron Basic Information, Anti-VEGF Injection Manufacturing Base, Sales Area and Its Competitors
Table 107. Regeneron Anti-VEGF Injection Product Portfolios and Specifications
Table 108. Regeneron Anti-VEGF Injection Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 109. Regeneron Main Business
Table 110. Regeneron Latest Developments
Table 111. Qilu Pharmaceutical Co.,Ltd. Basic Information, Anti-VEGF Injection Manufacturing Base, Sales Area and Its Competitors
Table 112. Qilu Pharmaceutical Co.,Ltd. Anti-VEGF Injection Product Portfolios and Specifications
Table 113. Qilu Pharmaceutical Co.,Ltd. Anti-VEGF Injection Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 114. Qilu Pharmaceutical Co.,Ltd. Main Business
Table 115. Qilu Pharmaceutical Co.,Ltd. Latest Developments
Table 116. Innovent Biologics Basic Information, Anti-VEGF Injection Manufacturing Base, Sales Area and Its Competitors
Table 117. Innovent Biologics Anti-VEGF Injection Product Portfolios and Specifications
Table 118. Innovent Biologics Anti-VEGF Injection Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 119. Innovent Biologics Main Business
Table 120. Innovent Biologics Latest Developments
Table 121. Anke Biotechnology Basic Information, Anti-VEGF Injection Manufacturing Base, Sales Area and Its Competitors
Table 122. Anke Biotechnology Anti-VEGF Injection Product Portfolios and Specifications
Table 123. Anke Biotechnology Anti-VEGF Injection Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 124. Anke Biotechnology Main Business
Table 125. Anke Biotechnology Latest Developments
Table 126. Shenzhen Kangzhe Pharmaceutical Co Ltd Basic Information, Anti-VEGF Injection Manufacturing Base, Sales Area and Its Competitors
Table 127. Shenzhen Kangzhe Pharmaceutical Co Ltd Anti-VEGF Injection Product Portfolios and Specifications
Table 128. Shenzhen Kangzhe Pharmaceutical Co Ltd Anti-VEGF Injection Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 129. Shenzhen Kangzhe Pharmaceutical Co Ltd Main Business
Table 130. Shenzhen Kangzhe Pharmaceutical Co Ltd Latest Developments
Table 131. Chengdu Kanghong Pharmaceutical Group Basic Information, Anti-VEGF Injection Manufacturing Base, Sales Area and Its Competitors
Table 132. Chengdu Kanghong Pharmaceutical Group Anti-VEGF Injection Product Portfolios and Specifications
Table 133. Chengdu Kanghong Pharmaceutical Group Anti-VEGF Injection Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 134. Chengdu Kanghong Pharmaceutical Group Main Business
Table 135. Chengdu Kanghong Pharmaceutical Group Latest Developments
LIST OF FIGURES
Figure 1. Picture of Anti-VEGF Injection
Figure 2. Anti-VEGF Injection Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Anti-VEGF Injection Sales Growth Rate 2019-2030 (K Units)
Figure 7. Global Anti-VEGF Injection Revenue Growth Rate 2019-2030 ($ Millions)
Figure 8. Anti-VEGF Injection Sales by Region (2019, 2023 & 2030) & ($ Millions)
Figure 9. Product Picture of Ranibizumab
Figure 10. Product Picture of Bevacizumab
Figure 11. Product Picture of Aflibercept
Figure 12. Product Picture of Brolucizumab
Figure 13. Product Picture of Others
Figure 14. Global Anti-VEGF Injection Sales Market Share by Type in 2023
Figure 15. Global Anti-VEGF Injection Revenue Market Share by Type (2019-2024)
Figure 16. Anti-VEGF Injection Consumed in Age-related Macular Degeneration (AMD)
Figure 17. Global Anti-VEGF Injection Market: Age-related Macular Degeneration (AMD) (2019-2024) & (K Units)
Figure 18. Anti-VEGF Injection Consumed in Diabetic Retinopathy
Figure 19. Global Anti-VEGF Injection Market: Diabetic Retinopathy (2019-2024) & (K Units)
Figure 20. Anti-VEGF Injection Consumed in Retinal Vein Occlusion (RVO)
Figure 21. Global Anti-VEGF Injection Market: Retinal Vein Occlusion (RVO) (2019-2024) & (K Units)
Figure 22. Anti-VEGF Injection Consumed in Retinopathy of Prematurity (ROP)
Figure 23. Global Anti-VEGF Injection Market: Retinopathy of Prematurity (ROP) (2019-2024) & (K Units)
Figure 24. Anti-VEGF Injection Consumed in Uveitis
Figure 25. Global Anti-VEGF Injection Market: Uveitis (2019-2024) & (K Units)
Figure 26. Anti-VEGF Injection Consumed in Neovascular Glaucoma
Figure 27. Global Anti-VEGF Injection Market: Neovascular Glaucoma (2019-2024) & (K Units)
Figure 28. Anti-VEGF Injection Consumed in Others
Figure 29. Global Anti-VEGF Injection Market: Others (2019-2024) & (K Units)
Figure 30. Global Anti-VEGF Injection Sales Market Share by Application (2023)
Figure 31. Global Anti-VEGF Injection Revenue Market Share by Application in 2023
Figure 32. Anti-VEGF Injection Sales Market by Company in 2023 (K Units)
Figure 33. Global Anti-VEGF Injection Sales Market Share by Company in 2023
Figure 34. Anti-VEGF Injection Revenue Market by Company in 2023 ($ Million)
Figure 35. Global Anti-VEGF Injection Revenue Market Share by Company in 2023
Figure 36. Global Anti-VEGF Injection Sales Market Share by Geographic Region (2019-2024)
Figure 37. Global Anti-VEGF Injection Revenue Market Share by Geographic Region in 2023
Figure 38. Americas Anti-VEGF Injection Sales 2019-2024 (K Units)
Figure 39. Americas Anti-VEGF Injection Revenue 2019-2024 ($ Millions)
Figure 40. APAC Anti-VEGF Injection Sales 2019-2024 (K Units)
Figure 41. APAC Anti-VEGF Injection Revenue 2019-2024 ($ Millions)
Figure 42. Europe Anti-VEGF Injection Sales 2019-2024 (K Units)
Figure 43. Europe Anti-VEGF Injection Revenue 2019-2024 ($ Millions)
Figure 44. Middle East & Africa Anti-VEGF Injection Sales 2019-2024 (K Units)
Figure 45. Middle East & Africa Anti-VEGF Injection Revenue 2019-2024 ($ Millions)
Figure 46. Americas Anti-VEGF Injection Sales Market Share by Country in 2023
Figure 47. Americas Anti-VEGF Injection Revenue Market Share by Country in 2023
Figure 48. Americas Anti-VEGF Injection Sales Market Share by Type (2019-2024)
Figure 49. Americas Anti-VEGF Injection Sales Market Share by Application (2019-2024)
Figure 50. United States Anti-VEGF Injection Revenue Growth 2019-2024 ($ Millions)
Figure 51. Canada Anti-VEGF Injection Revenue Growth 2019-2024 ($ Millions)
Figure 52. Mexico Anti-VEGF Injection Revenue Growth 2019-2024 ($ Millions)
Figure 53. Brazil Anti-VEGF Injection Revenue Growth 2019-2024 ($ Millions)
Figure 54. APAC Anti-VEGF Injection Sales Market Share by Region in 2023
Figure 55. APAC Anti-VEGF Injection Revenue Market Share by Regions in 2023
Figure 56. APAC Anti-VEGF Injection Sales Market Share by Type (2019-2024)
Figure 57. APAC Anti-VEGF Injection Sales Market Share by Application (2019-2024)
Figure 58. China Anti-VEGF Injection Revenue Growth 2019-2024 ($ Millions)
Figure 59. Japan Anti-VEGF Injection Revenue Growth 2019-2024 ($ Millions)
Figure 60. South Korea Anti-VEGF Injection Revenue Growth 2019-2024 ($ Millions)
Figure 61. Southeast Asia Anti-VEGF Injection Revenue Growth 2019-2024 ($ Millions)
Figure 62. India Anti-VEGF Injection Revenue Growth 2019-2024 ($ Millions)
Figure 63. Australia Anti-VEGF Injection Revenue Growth 2019-2024 ($ Millions)
Figure 64. China Taiwan Anti-VEGF Injection Revenue Growth 2019-2024 ($ Millions)
Figure 65. Europe Anti-VEGF Injection Sales Market Share by Country in 2023
Figure 66. Europe Anti-VEGF Injection Revenue Market Share by Country in 2023
Figure 67. Europe Anti-VEGF Injection Sales Market Share by Type (2019-2024)
Figure 68. Europe Anti-VEGF Injection Sales Market Share by Application (2019-2024)
Figure 69. Germany Anti-VEGF Injection Revenue Growth 2019-2024 ($ Millions)
Figure 70. France Anti-VEGF Injection Revenue Growth 2019-2024 ($ Millions)
Figure 71. UK Anti-VEGF Injection Revenue Growth 2019-2024 ($ Millions)
Figure 72. Italy Anti-VEGF Injection Revenue Growth 2019-2024 ($ Millions)
Figure 73. Russia Anti-VEGF Injection Revenue Growth 2019-2024 ($ Millions)
Figure 74. Middle East & Africa Anti-VEGF Injection Sales Market Share by Country in 2023
Figure 75. Middle East & Africa Anti-VEGF Injection Revenue Market Share by Country in 2023
Figure 76. Middle East & Africa Anti-VEGF Injection Sales Market Share by Type (2019-2024)
Figure 77. Middle East & Africa Anti-VEGF Injection Sales Market Share by Application (2019-2024)
Figure 78. Egypt Anti-VEGF Injection Revenue Growth 2019-2024 ($ Millions)
Figure 79. South Africa Anti-VEGF Injection Revenue Growth 2019-2024 ($ Millions)
Figure 80. Israel Anti-VEGF Injection Revenue Growth 2019-2024 ($ Millions)
Figure 81. Turkey Anti-VEGF Injection Revenue Growth 2019-2024 ($ Millions)
Figure 82. GCC Country Anti-VEGF Injection Revenue Growth 2019-2024 ($ Millions)
Figure 83. Manufacturing Cost Structure Analysis of Anti-VEGF Injection in 2023
Figure 84. Manufacturing Process Analysis of Anti-VEGF Injection
Figure 85. Industry Chain Structure of Anti-VEGF Injection
Figure 86. Channels of Distribution
Figure 87. Global Anti-VEGF Injection Sales Market Forecast by Region (2025-2030)
Figure 88. Global Anti-VEGF Injection Revenue Market Share Forecast by Region (2025-2030)
Figure 89. Global Anti-VEGF Injection Sales Market Share Forecast by Type (2025-2030)
Figure 90. Global Anti-VEGF Injection Revenue Market Share Forecast by Type (2025-2030)
Figure 91. Global Anti-VEGF Injection Sales Market Share Forecast by Application (2025-2030)
Figure 92. Global Anti-VEGF Injection Revenue Market Share Forecast by Application (2025-2030)
Figure 1. Picture of Anti-VEGF Injection
Figure 2. Anti-VEGF Injection Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Anti-VEGF Injection Sales Growth Rate 2019-2030 (K Units)
Figure 7. Global Anti-VEGF Injection Revenue Growth Rate 2019-2030 ($ Millions)
Figure 8. Anti-VEGF Injection Sales by Region (2019, 2023 & 2030) & ($ Millions)
Figure 9. Product Picture of Ranibizumab
Figure 10. Product Picture of Bevacizumab
Figure 11. Product Picture of Aflibercept
Figure 12. Product Picture of Brolucizumab
Figure 13. Product Picture of Others
Figure 14. Global Anti-VEGF Injection Sales Market Share by Type in 2023
Figure 15. Global Anti-VEGF Injection Revenue Market Share by Type (2019-2024)
Figure 16. Anti-VEGF Injection Consumed in Age-related Macular Degeneration (AMD)
Figure 17. Global Anti-VEGF Injection Market: Age-related Macular Degeneration (AMD) (2019-2024) & (K Units)
Figure 18. Anti-VEGF Injection Consumed in Diabetic Retinopathy
Figure 19. Global Anti-VEGF Injection Market: Diabetic Retinopathy (2019-2024) & (K Units)
Figure 20. Anti-VEGF Injection Consumed in Retinal Vein Occlusion (RVO)
Figure 21. Global Anti-VEGF Injection Market: Retinal Vein Occlusion (RVO) (2019-2024) & (K Units)
Figure 22. Anti-VEGF Injection Consumed in Retinopathy of Prematurity (ROP)
Figure 23. Global Anti-VEGF Injection Market: Retinopathy of Prematurity (ROP) (2019-2024) & (K Units)
Figure 24. Anti-VEGF Injection Consumed in Uveitis
Figure 25. Global Anti-VEGF Injection Market: Uveitis (2019-2024) & (K Units)
Figure 26. Anti-VEGF Injection Consumed in Neovascular Glaucoma
Figure 27. Global Anti-VEGF Injection Market: Neovascular Glaucoma (2019-2024) & (K Units)
Figure 28. Anti-VEGF Injection Consumed in Others
Figure 29. Global Anti-VEGF Injection Market: Others (2019-2024) & (K Units)
Figure 30. Global Anti-VEGF Injection Sales Market Share by Application (2023)
Figure 31. Global Anti-VEGF Injection Revenue Market Share by Application in 2023
Figure 32. Anti-VEGF Injection Sales Market by Company in 2023 (K Units)
Figure 33. Global Anti-VEGF Injection Sales Market Share by Company in 2023
Figure 34. Anti-VEGF Injection Revenue Market by Company in 2023 ($ Million)
Figure 35. Global Anti-VEGF Injection Revenue Market Share by Company in 2023
Figure 36. Global Anti-VEGF Injection Sales Market Share by Geographic Region (2019-2024)
Figure 37. Global Anti-VEGF Injection Revenue Market Share by Geographic Region in 2023
Figure 38. Americas Anti-VEGF Injection Sales 2019-2024 (K Units)
Figure 39. Americas Anti-VEGF Injection Revenue 2019-2024 ($ Millions)
Figure 40. APAC Anti-VEGF Injection Sales 2019-2024 (K Units)
Figure 41. APAC Anti-VEGF Injection Revenue 2019-2024 ($ Millions)
Figure 42. Europe Anti-VEGF Injection Sales 2019-2024 (K Units)
Figure 43. Europe Anti-VEGF Injection Revenue 2019-2024 ($ Millions)
Figure 44. Middle East & Africa Anti-VEGF Injection Sales 2019-2024 (K Units)
Figure 45. Middle East & Africa Anti-VEGF Injection Revenue 2019-2024 ($ Millions)
Figure 46. Americas Anti-VEGF Injection Sales Market Share by Country in 2023
Figure 47. Americas Anti-VEGF Injection Revenue Market Share by Country in 2023
Figure 48. Americas Anti-VEGF Injection Sales Market Share by Type (2019-2024)
Figure 49. Americas Anti-VEGF Injection Sales Market Share by Application (2019-2024)
Figure 50. United States Anti-VEGF Injection Revenue Growth 2019-2024 ($ Millions)
Figure 51. Canada Anti-VEGF Injection Revenue Growth 2019-2024 ($ Millions)
Figure 52. Mexico Anti-VEGF Injection Revenue Growth 2019-2024 ($ Millions)
Figure 53. Brazil Anti-VEGF Injection Revenue Growth 2019-2024 ($ Millions)
Figure 54. APAC Anti-VEGF Injection Sales Market Share by Region in 2023
Figure 55. APAC Anti-VEGF Injection Revenue Market Share by Regions in 2023
Figure 56. APAC Anti-VEGF Injection Sales Market Share by Type (2019-2024)
Figure 57. APAC Anti-VEGF Injection Sales Market Share by Application (2019-2024)
Figure 58. China Anti-VEGF Injection Revenue Growth 2019-2024 ($ Millions)
Figure 59. Japan Anti-VEGF Injection Revenue Growth 2019-2024 ($ Millions)
Figure 60. South Korea Anti-VEGF Injection Revenue Growth 2019-2024 ($ Millions)
Figure 61. Southeast Asia Anti-VEGF Injection Revenue Growth 2019-2024 ($ Millions)
Figure 62. India Anti-VEGF Injection Revenue Growth 2019-2024 ($ Millions)
Figure 63. Australia Anti-VEGF Injection Revenue Growth 2019-2024 ($ Millions)
Figure 64. China Taiwan Anti-VEGF Injection Revenue Growth 2019-2024 ($ Millions)
Figure 65. Europe Anti-VEGF Injection Sales Market Share by Country in 2023
Figure 66. Europe Anti-VEGF Injection Revenue Market Share by Country in 2023
Figure 67. Europe Anti-VEGF Injection Sales Market Share by Type (2019-2024)
Figure 68. Europe Anti-VEGF Injection Sales Market Share by Application (2019-2024)
Figure 69. Germany Anti-VEGF Injection Revenue Growth 2019-2024 ($ Millions)
Figure 70. France Anti-VEGF Injection Revenue Growth 2019-2024 ($ Millions)
Figure 71. UK Anti-VEGF Injection Revenue Growth 2019-2024 ($ Millions)
Figure 72. Italy Anti-VEGF Injection Revenue Growth 2019-2024 ($ Millions)
Figure 73. Russia Anti-VEGF Injection Revenue Growth 2019-2024 ($ Millions)
Figure 74. Middle East & Africa Anti-VEGF Injection Sales Market Share by Country in 2023
Figure 75. Middle East & Africa Anti-VEGF Injection Revenue Market Share by Country in 2023
Figure 76. Middle East & Africa Anti-VEGF Injection Sales Market Share by Type (2019-2024)
Figure 77. Middle East & Africa Anti-VEGF Injection Sales Market Share by Application (2019-2024)
Figure 78. Egypt Anti-VEGF Injection Revenue Growth 2019-2024 ($ Millions)
Figure 79. South Africa Anti-VEGF Injection Revenue Growth 2019-2024 ($ Millions)
Figure 80. Israel Anti-VEGF Injection Revenue Growth 2019-2024 ($ Millions)
Figure 81. Turkey Anti-VEGF Injection Revenue Growth 2019-2024 ($ Millions)
Figure 82. GCC Country Anti-VEGF Injection Revenue Growth 2019-2024 ($ Millions)
Figure 83. Manufacturing Cost Structure Analysis of Anti-VEGF Injection in 2023
Figure 84. Manufacturing Process Analysis of Anti-VEGF Injection
Figure 85. Industry Chain Structure of Anti-VEGF Injection
Figure 86. Channels of Distribution
Figure 87. Global Anti-VEGF Injection Sales Market Forecast by Region (2025-2030)
Figure 88. Global Anti-VEGF Injection Revenue Market Share Forecast by Region (2025-2030)
Figure 89. Global Anti-VEGF Injection Sales Market Share Forecast by Type (2025-2030)
Figure 90. Global Anti-VEGF Injection Revenue Market Share Forecast by Type (2025-2030)
Figure 91. Global Anti-VEGF Injection Sales Market Share Forecast by Application (2025-2030)
Figure 92. Global Anti-VEGF Injection Revenue Market Share Forecast by Application (2025-2030)
